Cognitive researchNot approved (US)

Adamax

Not medical advice. Educational reference only.

Route
Intranasal or injectable (research discussion)
Storage
Keep refrigerated at 2–8 °C and use within 28 days.

What is Adamax?

Adamax belongs to the Semax family of experimental nootropic peptides. Cognitive and neurological support are its main research interests, but clinical evidence directly addressing Adamax is limited. It has no FDA approval.

Research indications

  • Cognitive Function

    Effective

    Cognitive research examines possible improvements in memory, attention and information processing.

  • Neuroprotection

    Moderate

    Potential neuronal protection includes limiting damage caused by oxidative stress and inflammation.

  • Mood & Anxiety

    Moderate

    Some studies investigate reduced anxiety and more stable mood.

Interactions

  • Stimulants (Modafinil, Adderall)

    Caution
  • MAOIs / SSRIs

    Monitor
  • Racetams

    Caution
  • NAD+

    Compatible
  • BPC-157

    Compatible

How to reconstitute and inject

Diluent: Use bacteriostatic water only; avoid saline because it may cause precipitation.

  1. Take the Adamax vial out of the refrigerator and leave it for 15–20 minutes to reach room temperature.
  2. Disinfect the vial stopper with an alcohol swab. Wait until the alcohol has completely air-dried.
  3. Measure the calculated amount of bacteriostatic water into a sterile syringe. Use only bacteriostatic water; avoid saline because precipitation may occur.
  4. Add the water slowly along the inner wall of the vial. Keep the stream away from the powder itself.
  5. Rotate the vial gently to mix its contents. Never shake it vigorously, because this can degrade the peptide.
  6. Wait 2–3 minutes for the powder to dissolve completely. Check that the liquid is clear and has no color.
  7. Withdraw the calculated dose into an insulin syringe for administration beneath the skin.
  8. Inject into your abdomen, thigh or upper arm. Change the injection site each time to help prevent lipodystrophy.
  9. Refrigerate the mixed solution at 2–8 °C. Use it within 28 days after reconstitution.

What to expect

Week 1–2
Small improvements in mood and attention may emerge, with better sleep appearing early.
Week 2–4
Possible changes include clearer thinking, easier word retrieval and less brain fog.
Week 4–8
Cognitive changes may become more consistent, alongside improved working memory and responses to stress.
Week 8+
Cognitive and neurological effects may continue and can potentially last beyond the end of a cycle. These intervals are research expectations, not established individual outcomes.

Side effects and safety

  • Headache, especially when beginning use
  • Mild restlessness or anxiety with some compounds
  • Irritation of the nasal lining after intranasal administration
  • Disrupted sleep when dosing near bedtime
  • Changes in mood or emotional stability · Rare

Adamax: not approved in the US.

Regulatory status

  • US

    Not approved

    FDA — research use only; no approval.

    Rx required
    No
    503A
    Allowed
    Telehealth
    N/A

Frequently asked questions

What is Adamax?

Adamax belongs to the Semax family of experimental nootropic peptides. Cognitive and neurological support are its main research interests, but clinical evidence directly addressing Adamax is limited. It has no FDA approval.

What research applications are being explored for Adamax?

Research explores cognitive function and neurological support, including memory, attention and protection of neurons. Investigation is ongoing, and the indication ratings do not establish an approved treatment. Discuss any proposed use with a qualified healthcare professional.

Which doses appear in research discussions?

Starting dose: an unspecified low dose once daily, using an intranasal or injectable route. Standard dose: an unspecified standard amount once daily by either route. Neither schedule supplies a numeric dose. Consult a qualified clinician and current literature for dosing guidance specific to the indication.

What safety concerns need consideration?

The dose, administration route and individual response influence adverse effects. Human studies have not fully characterized compound-specific risks. Headache, restlessness, nasal irritation and sleep changes are potential concerns in cognitive-compound discussions. Ask a qualified healthcare professional about individual risk.

References

  1. Semax and its derivatives: neuroprotective peptides (review) (2018)

  2. Semax, an analog of ACTH(4-7), regulates expression of immune response genes (2013)